A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Open Access
- 29 February 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (5), 1095-1102
- https://doi.org/10.1158/1078-0432.ccr-15-1718
Abstract
See manuscript- over 250 word count at reviewer's request. Additional word count was approved by Cara Vandy.Keywords
Other Versions
This publication has 14 references indexed in Scilit:
- LY2228820 Dimesylate, a Selective Inhibitor of p38 Mitogen-activated Protein Kinase, Reduces Angiogenic Endothelial Cord Formation in Vitro and in VivoJournal of Biological Chemistry, 2013
- Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndromeLeukemia, 2012
- Hallmarks of cancer: Interactions with the tumor stromaExperimental Cell Research, 2010
- p38MAPK: stress responses from molecular mechanisms to therapeuticsTrends in Molecular Medicine, 2009
- An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer CellsMolecular Cancer Research, 2008
- p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsBritish Journal of Haematology, 2008
- Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein KinaseJournal of Clinical Oncology, 2005
- Stromal fibroblasts in cancer initiation and progressionNature, 2004
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000